Arcus Biosciences Inc (RCUS)

Total asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	117,000	119,355	121,236	118,995	112,000	433,144	408,724	399,137	398,304	53,292	108,361	92,939	77,517	77,780	15,000	15,000	15,000	6,812	9,353	8,853
Total assets	US$ in thousands	1,095,000	1,191,000	1,220,000	1,254,000	1,345,000	1,393,820	1,476,770	1,543,430	1,592,000	839,290	898,773	935,119	772,292	811,075	481,389	176,144	203,110	216,957	238,974	258,530
Total asset turnover		0.11	0.10	0.10	0.09	0.08	0.31	0.28	0.26	0.25	0.06	0.12	0.10	0.10	0.10	0.03	0.09	0.07	0.03	0.04	0.03

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $117,000K ÷ $1,095,000K
= 0.11

The total asset turnover ratio for Arcus Biosciences Inc has shown a declining trend from Q1 2022 to Q1 2023, indicating that the company's ability to generate sales from its total assets has weakened over this period. In Q4 2022, the ratio was at its lowest point of 0.08, signaling a decrease in efficiency in utilizing its assets to generate revenue.

However, a notable improvement was seen in Q3 2022 when the ratio spiked to 0.31, suggesting a significant boost in operational efficiency and the company's ability to generate sales relative to its total assets. This peak was followed by a gradual decline in subsequent quarters.

Overall, the fluctuating trend in the total asset turnover ratio for Arcus Biosciences Inc indicates varying levels of asset utilization efficiency over the analyzed period, with the company facing challenges in consistently converting its assets into revenue.